Sara Corvigno1, Jared K Burks2, Wei Hu1, Yanping Zhong3,4, Nicholas B Jennings1, Nicole D Fleming1, Shannon N Westin1, Bryan Fellman5, Jinsong Liu3, Anil K Sood6,7. 1. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77054, USA. 2. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Anatomic Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Department of Pathology, The First Hospital of Jilin University, Changchun, 130021, Jilin, China. 5. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 6. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77054, USA. asood@mdanderson.org. 7. Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. asood@mdanderson.org.
Abstract
PURPOSE: An in-depth analysis of the tumor microenvironment of ovarian cancer is needed. The purpose of this study was to elucidate the architecture of the immune microenvironment of high-grade serous ovarian cancers (HGSCs) with or without BRCA1 and BRCA2 mutations. METHODS: A cohort of highly annotated HGSC patients with known germline BRCA1 and BRCA2 status was selected, and pretreatment tumor tissue specimens were analyzed with a multiplexed staining technique aimed at detecting lymphocytes, macrophages, and fibroblasts in the whole tumor area and in specific regions including epithelium, stroma, and perivascular areas. RESULTS: BRCA1- or BRCA2-mutated tumors showed a more immunogenic microenvironment, characterized by a higher abundance of CD8+ and PD-L1+ cells, than did tumors with wild-type BRCA1 and BRCA2. High numbers of PD-L1+ and PD-L1+CD8+ cells were prognostic for event-free survival (hazard ratio [HR]: 0.41, 95% CI 0.21-0.79, p = 0.008 and HR 0.49, 95% CI 0.26-0.91, p = 0.025, respectively), as were high numbers of epithelial PD-L1+ and FAP+PD-L1+ cells (HR 0.52, 95% CI 0.28-0.96, p = 0.037 and HR 0.27, 95% CI 0.08-0.87, p = 0.029) and CD8+ cells (HR 0.51, 95% CI 0.28-0.93, p = 0.027). CONCLUSIONS: This study reveals substantial differences between the immune microenvironment composition of germline BRCA-mutated and BRCA wild-type HGSC.
PURPOSE: An in-depth analysis of the tumor microenvironment of ovarian cancer is needed. The purpose of this study was to elucidate the architecture of the immune microenvironment of high-grade serous ovarian cancers (HGSCs) with or without BRCA1 and BRCA2 mutations. METHODS: A cohort of highly annotated HGSC patients with known germline BRCA1 and BRCA2 status was selected, and pretreatment tumor tissue specimens were analyzed with a multiplexed staining technique aimed at detecting lymphocytes, macrophages, and fibroblasts in the whole tumor area and in specific regions including epithelium, stroma, and perivascular areas. RESULTS: BRCA1- or BRCA2-mutated tumors showed a more immunogenic microenvironment, characterized by a higher abundance of CD8+ and PD-L1+ cells, than did tumors with wild-type BRCA1 and BRCA2. High numbers of PD-L1+ and PD-L1+CD8+ cells were prognostic for event-free survival (hazard ratio [HR]: 0.41, 95% CI 0.21-0.79, p = 0.008 and HR 0.49, 95% CI 0.26-0.91, p = 0.025, respectively), as were high numbers of epithelial PD-L1+ and FAP+PD-L1+ cells (HR 0.52, 95% CI 0.28-0.96, p = 0.037 and HR 0.27, 95% CI 0.08-0.87, p = 0.029) and CD8+ cells (HR 0.51, 95% CI 0.28-0.93, p = 0.027). CONCLUSIONS: This study reveals substantial differences between the immune microenvironment composition of germline BRCA-mutated and BRCA wild-type HGSC.
Authors: Romualdo Barroso-Sousa; Tanya E Keenan; Eliezer M Van Allen; Sara M Tolaney; Sonia Pernas; Pedro Exman; Esha Jain; Ana C Garrido-Castro; Melissa Hughes; Brittany Bychkovsky; Renato Umeton; Janet L Files; Neal I Lindeman; Laura E MacConaill; F Stephen Hodi; Ian E Krop; Deborah Dillon; Eric P Winer; Nikhil Wagle; Nancy U Lin; Elizabeth A Mittendorf Journal: Clin Cancer Res Date: 2020-02-04 Impact factor: 12.531
Authors: P M L H Vencken; M Kriege; D Hoogwerf; S Beugelink; M E L van der Burg; M J Hooning; E M Berns; A Jager; M Collée; C W Burger; C Seynaeve Journal: Ann Oncol Date: 2011-01-12 Impact factor: 32.976
Authors: Kyle C Strickland; Brooke E Howitt; Sachet A Shukla; Scott Rodig; Lauren L Ritterhouse; Joyce F Liu; Judy E Garber; Dipanjan Chowdhury; Catherine J Wu; Alan D D'Andrea; Ursula A Matulonis; Panagiotis A Konstantinopoulos Journal: Oncotarget Date: 2016-03-22
Authors: Maureen L Drakes; Swati Mehrotra; Monica Aldulescu; Ronald K Potkul; Yueying Liu; Anne Grisoli; Cara Joyce; Timothy E O'Brien; M Sharon Stack; Patrick J Stiff Journal: J Ovarian Res Date: 2018-05-30 Impact factor: 4.234
Authors: Laura Martin de la Fuente; Sofia Westbom-Fremer; Nicolai Skovbjerg Arildsen; Linda Hartman; Susanne Malander; Päivi Kannisto; Anna Måsbäck; Ingrid Hedenfalk Journal: Virchows Arch Date: 2020-01-24 Impact factor: 4.064